Hyperphosphatemia and phosphate binders: effectiveness and safety

References

• Moe SM. Disorders involving calcium, phosphorus, and magnesium. Prim Care 2008;35:215-vi
   PubMed Web of Science ®Google Scholar
• Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17
   PubMed Web of Science ®Google Scholar
• Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000;87:E10-17
   PubMed Web of Science ®Google Scholar
• Jamal SA, Fitchett D, Lok CE, et al. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant 2009;24:3168-74
   PubMed Web of Science ®Google Scholar
• Ohtake T, Ishioka K, Honda K, et al. Impact of coronary artery calcification in hemodialysis patients: risk factors and associations with prognosis. Hemodial Int 2010;14:218-25
   PubMed Web of Science ®Google Scholar
• Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18
   PubMed Web of Science ®Google Scholar
• Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO (4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-8
   PubMed Web of Science ®Google Scholar
• Foley RN, Collins AJ, Herzog CA, et al. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 2009;20:397-404
   PubMed Web of Science ®Google Scholar
• Neves KR, Graciolli FG, dos Reis LM, et al. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int 2004;66:2237-44
   PubMed Web of Science ®Google Scholar
• Bellasi A, Mandreoli M, Baldrati L, et al. Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction. Clin J Am Soc Nephrol 2011;6:883-91
   PubMed Web of Science ®Google Scholar
• Zoccali C, Ruggenenti P, Perna A, et al. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol 2011;22:1923-30
   PubMed Web of Science ®Google Scholar
• Lee H, Oh SW, Heo NJ, et al. Serum phosphorus as a predictor of low-grade albuminuria in a general population without evidence of chronic kidney disease. Nephrol Dial Transplant 2012;27:2799-806
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771-80
   PubMed Web of Science ®Google Scholar
• Chue CD, Townend JN, Moody WE, et al. Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol 2013;24:842-52
   PubMed Web of Science ®Google Scholar
• Parkinson IS, Ward MK, Feest TG, et al. Fracturing dialysis osteodystrophy and dialysis encephalopathy. An epidemiological survey. Lancet 1979;1:406-9
   PubMed Web of Science ®Google Scholar
• Chertow GM, Raggi P, Chasan-Taber S, et al. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004;19:1489-96
   PubMed Web of Science ®Google Scholar
• Di IB, Nargi O, Cucciniello E, et al. Coronary artery calcification progression is associated with arterial stiffness and cardiac repolarization deterioration in hemodialysis patients. Kidney Blood Press Res 2011;34:180-7
   PubMed Web of Science ®Google Scholar
• Draca N, Lazic R, Simic P, et al. Potential beneficial role of sevelamer hydrochloride in diabetic retinopathy. Med Hypotheses 2013;80:431-5
   PubMed Web of Science ®Google Scholar
• Covic A, Passlick-Deetjen J, Kroczak M, et al. A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. 2013;28:2383-92. doi: 10.1093/ndt/gft203
   Google Scholar
• Finn WF, Joy MS, Hladik G. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 2004;62:193-201
   PubMed Web of Science ®Google Scholar
• Huang W, Liu J, Tang Y, . Efficacy and tolerability of lanthanum carbonate in treatment of hyperphosphatemia patients receiving dialysis – a systematic review and meta-analysis of randomized controlled trials. Curr Med Res Opin 2014;30:99-108
   PubMed Web of Science ®Google Scholar
• Navaneethan SD, Palmer SC, Craig JC, et al. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009;54:619-37
   PubMed Web of Science ®Google Scholar
• Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013;Jul 18. pii: S0140-6736(13)60897-1. doi: 10.1016/S0140-6736(13)60897-1. [Epub ahead of print]
   Google Scholar
• Ohtake T, Kobayashi S, Oka M, et al. Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study. J Cardiovasc Pharmacol Ther 2013;18:439-6. doi: 10.1177/1074248413486355
   Google Scholar
• Negi S, Shigematsu T. [CKD-MBD (chronic kidney disease–mineral and bone disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease]. Clin Calcium 2010;20:1096-102 . doi: CliCa100710961102
   PubMedGoogle Scholar